These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31733184)

  • 1. Two Distinct Tumorigenic Processes in Endometrial Endometrioid Adenocarcinoma.
    Sugiyama Y; Gotoh O; Fukui N; Tanaka N; Hasumi K; Takazawa Y; Noda T; Mori S
    Am J Pathol; 2020 Jan; 190(1):234-251. PubMed ID: 31733184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Expression of IR-A, IR-B and IGF-1R in Endometrial Physiology and Distinct Signature in Adenocarcinoma.
    Flannery CA; Saleh FL; Choe GH; Selen DJ; Kodaman PH; Kliman HJ; Wood TL; Taylor HS
    J Clin Endocrinol Metab; 2016 Jul; 101(7):2883-91. PubMed ID: 27088794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiles of benign and (pre)malignant endometrial lesions.
    van der Putten LJM; van Hoof R; Tops BBJ; Snijders MPLM; van den Berg-van Erp SH; van der Wurff AAM; Bulten J; Pijnenborg JMA; Massuger LFAG
    Carcinogenesis; 2017 Mar; 38(3):329-335. PubMed ID: 28203752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and epigenetic alterations in precursor lesions of endometrial endometrioid carcinoma.
    Gotoh O; Sugiyama Y; Tonooka A; Kosugi M; Kitaura S; Minegishi R; Sano M; Amino S; Furuya R; Tanaka N; Kaneyasu T; Kumegawa K; Abe A; Nomura H; Takazawa Y; Kanao H; Maruyama R; Noda T; Mori S
    J Pathol; 2024 Jul; 263(3):275-287. PubMed ID: 38734880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications.
    Orlandi A; Ferlosio A; Ciucci A; Francesconi A; Lifschitz-Mercer B; Gabbiani G; Spagnoli LG; Czernobilsky B
    Mod Pathol; 2006 Jun; 19(6):797-803. PubMed ID: 16575402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer.
    Deng L; Broaddus RR; McCampbell A; Shipley GL; Loose DS; Stancel GM; Pickar JH; Davies PJ
    Clin Cancer Res; 2005 Dec; 11(23):8258-64. PubMed ID: 16322283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
    Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
    Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].
    Lax S
    Pathologe; 2011 Nov; 32 Suppl 2():255-64. PubMed ID: 22033684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
    Chapel DB; Patil SA; Plagov A; Puranik R; Mendybaeva A; Steinhardt G; Wanjari P; Lastra RR; Kadri S; Segal JP; Ritterhouse LL
    Mod Pathol; 2019 Oct; 32(10):1508-1520. PubMed ID: 31186530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
    Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
    PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of ovarian hyperthecosis with endometrial polyp, endometrial hyperplasia, and endometrioid adenocarcinoma in postmenopausal women: a clinicopathological study of 238 cases.
    Zhang C; Sung CJ; Quddus MR; Simon RA; Jazaerly T; Lawrence WD
    Hum Pathol; 2017 Jan; 59():120-124. PubMed ID: 27746268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update.
    Horn LC; Meinel A; Handzel R; Einenkel J
    Ann Diagn Pathol; 2007 Aug; 11(4):297-311. PubMed ID: 17630117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma.
    Duan C; Liu X; Liang S; Yang Z; Xia M; Wang L; Chen S; Yu L
    J Cell Mol Med; 2014 May; 18(5):863-74. PubMed ID: 24495253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases.
    Němejcová K; Rosmusová J; Bártů M; Důra M; Tichá I; Dundr P
    Int J Surg Pathol; 2017 Aug; 25(5):389-396. PubMed ID: 28381136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
    Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
    Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
    Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.